Profound Medical focuses on incision-free therapies for diseased tissue with its TULSA-PRO system for prostate ablation. The device uses real-time MRI guidance, robotic transurethral ultrasound, and closed-loop temperature control to ablate targeted prostate tissue in a single outpatient session. Revenue comes from a razor-blade model: upfront capital equipment plus recurring income from consumables, leases, and services, with AI-powered TULSA-AI modules under development. The goal is to expand precise, noninvasive prostate treatment to major hospitals and imaging centers while growing recurring revenue and usability.
Company Size
51-200
Company Stage
Post IPO Equity
Headquarters
Mississauga, Canada
Founded
2008
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?